
Bodyport
Predicting and preventing heart disease.
- Founded
- 2015
- Status
- Active
- Stage
- Growth
- Team size
- 19
- Location
- San Francisco, CA, USA
- Category
- Medical Devices & Diagnostics
- Sector
- Consumer Health and Wellness
About Bodyport
Bodyport’s cardiovascular sensing weight scale and predictive algorithms detect early changes in cardiac function to help prevent avoidable hospitalizations. Bodyport is initially targeting heart failure, a chronic condition affecting over 6M Americans and a leading cause of hospitalizations (1M/year) and healthcare spending ($35B/year). Bodyport’s novel scale measures cardiac output, congestion, heart rate, and other leading indicators of cardiovascular health — all in the same step patients already take to weigh themselves. Companion algorithms and software empower care teams to quickly identify at-risk patients and remotely optimize their therapy to prevent deterioration.
FDA clearances
1 510(k) clearance on record, 2022.
- Bodyport Cardiac Scale
K211585
Source: FDA 510(k) database via openFDA.
Clinical trials
3 registered trials with this company as lead sponsor, 2021 to 2025.
- Status
- Completed (1), Recruiting (2)
- Conditions
- Heart Failure, Kidney Disease, Peritoneal Dialysis (PD), End Stage Kidney Disease (ESRD)
NCT04882449, NCT07205120, NCT07059962
Source: ClinicalTrials.gov.
Company data compiled and maintained by Healthcare Discovery.
